Literature DB >> 17011867

Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization.

Vincenzo Isola1, Alfredo Pece, Maurizio Battaglia Parodi.   

Abstract

PURPOSE: To report delay in choroidal perfusion suggestive of ischemia after photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV).
DESIGN: Observational case series.
METHODS: Retrospective review of all patients who developed choroidal ischemia after PDT.
RESULTS: This vascular change was found in eight (2.1%) of 373 eyes of patients treated for CNV as a result of age-related macular degeneration (AMD) and in one (0.9%) of 114 eyes treated for pathologic myopia. A decrease of 3 lines of vision was reported to occur one week after treatment in patients with AMD. At the 12-month examination, patients did not exhibit any marked changes in visual acuity.
CONCLUSIONS: Choroidal ischemia was an uncommon manifestation owing to the selectivity of verteporfin therapy and the existence of abundant anastomotic vascular connections in the choroid. The low incidence of this vascular event should not preclude counseling PDT in eyes that could benefit greatly from this therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011867     DOI: 10.1016/j.ajo.2006.04.028

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Colin S Tan; Kai Xiong Cheong; Louis W Lim; Shoun Tan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-09       Impact factor: 3.117

2.  Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yukinori Sugano; Tomohiro Iida; Ichiro Maruko; Akira Ojima; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2013-02-14       Impact factor: 2.447

3.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

4.  Combined treatment of photodynamic therapy and bevacizumab for choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Hyun Woong Kim; Jung Lim Kim; Mi Hyun Lee; Hyung Gon Yoo; In Young Chung; Ji Eun Lee
Journal:  Korean J Ophthalmol       Date:  2011-07-22

Review 5.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

6.  Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis).

Authors:  Gregg T Kokame
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

7.  Subfoveal choroidal neovascularization in a patient with hemicentral vein occlusion.

Authors:  Antonio Fea; Andrea Grosso; Massimo Mollo; Federico M Grignolo
Journal:  Int Ophthalmol       Date:  2009-05-09       Impact factor: 2.031

8.  Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.

Authors:  Xiaojuan Fan; Ning Gao; Jingming Li; Jianqin Lei; Qianyan Kang
Journal:  Mol Cell Biochem       Date:  2017-09-07       Impact factor: 3.396

9.  Severe decrease in visual acuity with choroidal hypoperfusion after photodynamic therapy.

Authors:  Małgorzata Figurska; Joanna Wierzbowska; Jacek Robaszkiewicz
Journal:  Med Sci Monit       Date:  2011-06

10.  Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Shun Kumashiro; Seiji Takagi; Takashi Itokawa; Akiko Tajima; Tatsuhiko Kobayashi; Yuichi Hori
Journal:  BMC Ophthalmol       Date:  2021-05-31       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.